CM
SRPT icon

Caption Management’s Sarepta Therapeutics SRPT Stock Holding History

Caption Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.64M Sell
167,500
-17,200
-9% -$333K 0.02% 626
2025
Q4 		$3.97M Sell
184,700
-485,900
-72% -$10.2M 0.03% 587
2025
Q3 		$12.9M Sell
670,600
-227,800
-25% -$4.06M 0.1% 216
2025
Q2 		$15.4M Buy
898,400
+847,400
+1,662% +$36.2M 0.17% 121
2025
Q1 		$3.25M Buy
51,000
+26,000
+104% +$2.74M 0.03% 527
2024
Q4 		$3.04M Sell
25,000
-7,500
-23% -$919K 0.03% 545
2024
Q3 		$4.06M Sell
32,500
-312,300
-91% -$43.2M 0.06% 351
2024
Q2 		$54.5M Sell
344,800
-438,200
-56% -$56.3M 0.84% 22
2024
Q1 		$101M Sell
783,000
-181,300
-19% -$22.2M 1.54% 6
2023
Q4 		$93M Buy
964,300
+308,200
+47% +$29.6M 1.25% 8
2023
Q3 		$79.5M Buy
656,100
+394,700
+151% +$44.6M 1.22% 5
2023
Q2 		$29.9M Sell
261,400
-55,000
-17% -$7.09M 0.53% 27
2023
Q1 		$43.6M Buy
316,400
+18,000
+6% +$2.33M 0.84% 16
2022
Q4 		$38.7M Buy
298,400
+121,000
+68% +$14M 0.6% 27
2022
Q3 		$19.6M Sell
177,400
-20,500
-10% -$2.07M 0.27% 70
2022
Q2 		$14.8M Buy
197,900
+93,000
+89% +$6.84M 0.2% 112
2022
Q1 		$8.2M Sell
104,900
-212,600
-67% -$16.3M 0.1% 280
2021
Q4 		$28.6M Buy
317,500
+268,400
+547% +$22.9M 0.32% 51
2021
Q3 		$4.54M Sell
49,100
-32,200
-40% -$2.48M 0.05% 490
2021
Q2 		$6.32M Buy
+81,300
New +$6.16M 0.08% 316
2021
Q1 		– Sell
-65,000
Closed -$11.1M – 1372
2020
Q4 		$11.1M Buy
65,000
+55,000
+550% +$8.15M 0.25% 104
2020
Q3 		$1.4M Sell
10,000
-40,000
-80% -$6.08M 0.03% 534
2020
Q2 		$8.02M Sell
50,000
-105,000
-68% -$14.3M 0.27% 94
2020
Q1 		$15.2M Buy
155,000
+70,000
+82% +$8M 0.86% 9
2019
Q4 		$11M Buy
85,000
+10,000
+13% +$1.01M 0.37% 56
2019
Q3 		$5.65M Sell
75,000
-2,900
-4% -$342K 0.29% 95
2019
Q2 		$11.8M Buy
77,900
+67,900
+679% +$8.25M 0.6% 31
2019
Q1 		$1.19M Buy
+10,000
New +$1.29M 0.07% 317

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caption Management's SRPT Position: Q1 2026 in Review

Caption Management increased its Sarepta Therapeutics (SRPT) stake by 42% in Q1 2026, buying an estimated $329K and bringing the position to 57,890 shares worth $1.26M. The position accounts for 0.01% of the portfolio, ranked #947.

Caption Management first reported a position in SRPT in Q1 2019 and has held it in 13 quarters since. The position peaked at $35.9M in Q2 2024. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Caption Management held 57,890 shares of Sarepta Therapeutics worth $1.26M as of Q1 2026.
  • Caption Management bought 17,000 Sarepta Therapeutics shares in Q1 2026, an estimated $329K.
  • Sarepta Therapeutics made up 0.01% of Caption Management's portfolio in Q1 2026, its #947 holding.
  • Caption Management first reported a position in Sarepta Therapeutics in Q1 2019 and has held it in 13 quarters since.
  • Caption Management's Sarepta Therapeutics position peaked at $35.9M in Q2 2024.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.